Saturday 17 October 2026
Export INBX’s income statement to Excel — free account
Inhibrx Biosciences, Inc.
INBX Healthcare Biotechnology
Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024. In the quarter to June 2026, revenue grew 992.4%, EPS fell 26.5%, free cash flow was flat and total debt rose 77.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
89.83
0.67
−0.74%
Follow INBX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | — | — |
P/E ratio |
0.00 | 0.13 | 0.00 | 0.00 |
Altman Z-Score |
0.73 | (3.18) | — | — |
P/S ratio |
388.28 | 115.71 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(7.18) | (6.92) | (6.02) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
0.31 | 43.81 | (2.00) | — |
P/Operating CF |
(40.62) | (5.21) | (2.71) | (2.71) |
P/B ratio |
153.07 | 1.71 | 0.00 | 0.00 |
Price to Tangible BV |
153.07 | 1.71 | 0.00 | 0.00 |
EV/Sales |
380.77 | 143.31 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(9.24) | (1.45) | (0.60) | (0.60) |
EV/FCF |
(9.24) | (1.43) | (0.58) | (0.58) |
Quick Ratio |
3.68 | 3.76 | 4.95 | 0.01 |
Current Ratio |
3.93 | 3.94 | 5.25 | 0.30 |
Net Debt/EBITDA |
0.18 | 0.46 | 0.33 | 0.00 |
Debt/Assets |
68.65% | 0.00% | 67.22% | 0.00% |
Debt/Equity |
12.58 | 0.00 | 4.76 | 0.00 |
Asset Turnover |
0.01 | 0.00 | 0.01 | 0.00 |
Operating CF/Net income |
0.93 | (0.12) | 0.80 | 0.79 |
Capex/Depreciation |
(0.01) | (1.14) | (3.86) | (0.56) |
Interest Coverage |
(11.07) | (24.57) | (6.89) | — |
| (197.85%) | 1,905.92% | (1,333.38%) | 0.00% | |
| (85.60%) | 690.69% | (148.74%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(136.29%) | 1,340.75% | (98.33%) | 960.40% |
Average Days of Receivables |
49.70 | 766.50 | 157.76 | 71.33 |
Research and Development Expense of Revenue |
8,694.46% | 101,871.50% | 10,646.67% | 7,726.46% |
Selling, General and Administrative Expense of Revenue |
1,792.08% | 63,952.50% | 1,632.28% | 1,143.35% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
856.77% | 29,259.00% | 1,380.33% | 1,352.93% |
Graham Net Nets |
0.00 | 0.50 | (0.15) | (0.15) |
Graham Number |
0.00 | 153.08 | 0.00 | 0.00 |
Earnings Yield |
(11.44%) | 749.34% | (209.87%) | (209.87%) |
Free Cash Flow Yield |
(10.61%) | (86.42%) | (100.11%) | (100.11%) |
Revenue per Share |
0.08 | 0.01 | 0.15 | 0.00 |
Operating CF per Share |
(8.38) | (13.13) | (16.41) | 0.00 |
Capex per Share |
0.00 | (0.18) | (0.39) | 0.00 |
Free Cash Flow per Share |
(8.38) | (13.31) | (16.80) | 0.00 |
Cash per Share |
8.02 | 10.31 | 23.59 | — |
Shareholders Equity per Share |
0.52 | 9.02 | 3.69 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.52 | 9.02 | 3.69 | 0.00 |
Free Cash Flow |
(129.82) | (197.01) | (197.90) | (91.50) |
Working Capital |
99.03 | 119.67 | 239.05 | (14.51) |
Capital Expenditures |
(0.03) | (2.60) | (4.59) | (0.69) |
Net Current Asset Value |
(5.65) | 113.22 | 30.97 | (17.68) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 12.99 | 2.55 | 0.52 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.67 | 0.37 | 0.19 | 0.49 |
Cash ROIC |
(55.77%) | (68.84%) | (37.45%) | 1,253.38% |
Accounts Receivable Turnover |
4.36 | 0.33 | 3.48 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.30 | 0.60 | 0.52 | — |
Average Payables |
7.59 | 10.10 | 7.65 | — |
Average Assets |
163.62 | 244.33 | 162.27 | — |
Average Common Equity |
70.79 | 88.54 | 18.10 | — |
Columns are period end dates